HALO Halozyme Therapeutics
- 38.570
- +0.110+0.29%
- 37.130
- -1.440-3.73%
Halozyme Therapeutics News
Halozyme Therapeutics Insider Lowered Holding By 62% During Last Year
Looking at Halozyme Therapeutics, Inc.'s (NASDAQ:HALO ) insider transactions over the last year, we can see that insiders were net sellers. That is, there were more number of shares sold by insiders t
Express News | Mahesh Krishnan Elected to Halozyme's Board of Directors
Halozyme to Report First Quarter 2024 Financial and Operating Results
Halozyme Therapeutics, Inc. (NASDAQ: HALO) ("Halozyme") today announced it will release its first quarter 2024 financial and operating results on...
Halozyme Therapeutics (HALO) Is an Incredible Growth Stock: 3 Reasons Why
Halozyme Therapeutics (HALO) Upgraded to Buy: Here's What You Should Know
Halozyme Therapeutics Insider Sold Shares Worth $768,390, According to a Recent SEC Filing
Michael J. LaBarre, SVP, CHIEF TECHNICAL OFFICER, around April 16, 2024, sold 20,000 shares in Halozyme Therapeutics (HALO) for $768,390. Following the Form 4 filing with the SEC, LaBarre has control
Halozyme Therapeutics(HALO.US) Officer Sells US$768.39K in Common Stock
$Halozyme Therapeutics(HALO.US)$ Officer LaBarre Michael J. sold 20,000 shares of common stock on Apr 16, 17, 2024 at an average price of $38.42 for a total value of $768.39K.Source: Announcement What
Form 144 | Halozyme Therapeutics(HALO.US) Officer Proposes to Sell 384.89K in Common Stocks
SEC FILLINGS DISCLOSED/ Apr 17, $Halozyme Therapeutics(HALO.US)$ Officer MICHAEL LABARRE intends to sell 10,000 shares of its common stock on Apr 17, with a total market value of approximately $384.89
Express News | HC Wainwright & Co. Reiterates Buy on Halozyme Therapeutics, Maintains $50 Price Target
Form 144 | Halozyme Therapeutics(HALO.US) Officer Proposes to Sell 383.5K in Common Stocks
SEC FILLINGS DISCLOSED/ Apr 16, $Halozyme Therapeutics(HALO.US)$ Officer MICHAEL LABARRE intends to sell 10,000 shares of its common stock on Apr 16, with a total market value of approximately $383.5K
9 Analysts Have This To Say About Halozyme Therapeutics
Analysts' ratings for Halozyme Therapeutics (NASDAQ:HALO) over the last quarter vary from bullish to bearish, as provided by 9 analysts.The table below offers a condensed view of their recent ratings,
Express News | Benchmark Reiterates Buy on Halozyme Therapeutics, Maintains $50 Price Target
Halozyme Therapeutics Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 04/16/2024 29.13% Benchmark → $50 Reiterates Buy → Buy 02/29/2024 39.46% TD Cowen → $54 Initiates Coverage
S&P 500 Futures Up In Premarket Trading; Halozyme Therapeutics, Revvity Lead
This article was automatically generated by Barrons.com using technology from Automated Insights. With U.S. stock markets set to open in two hours, Halozyme Therapeutics Inc. (HALO) was up 7.7% in pr
Why Biophytis Shares Are Trading Higher By Around 55%; Here Are 20 Stocks Moving Premarket
Shares of Biophytis S.A. (NASDAQ:BPTS) rose sharply in today's pre-market trading after reporting FY23 results. Biophytis posted a FY23 loss of €0.03 per share, versus a year-ago loss of €0.14 per s
Is Now The Time To Put Halozyme Therapeutics (NASDAQ:HALO) On Your Watchlist?
For beginners, it can seem like a good idea (and an exciting prospect) to buy a company that tells a good story to investors, even if it currently lacks a track record of revenue and profit. But the
S&P 500 Futures Up In Premarket Trading; Leonardo DRS, Thomson Reuters Lead
This article was automatically generated by Barrons.com using technology from Automated Insights. With U.S. stock markets set to open in two hours, Leonardo DRS Inc. (DRS) was up 5.0% in pre-market t
Mirum Pharmaceuticals (MIRM) Down 12.5% Since Last Earnings Report: Can It Rebound?
Xeris Gains as Oppenheimer Highlights Drug Technology
Why Is Denali Therapeutics (DNLI) Up 2.8% Since Last Earnings Report?
Analysis
Price Target
No Data
